Inhibition of UGT8 suppresses basal-like breast cancer progression by attenuating sulfatide-αVβ5 axis.

Inhibition of UGT8 suppresses basal-like breast cancer progression by attenuating sulfatide-αVβ5 axis.
复制标题

抑制 UGT8 通过减弱硫苷脂-α V β 5 轴抑制基底样乳腺癌进展

DOI:
10.1084/jem.20172048
复制
发表时间:
2018-06-04
期刊:
The Journal of experimental medicine
影响因子:
--
通讯作者:
Dong C
Dong C
中科院分区:
其他
文献类型:
--
作者:
Cao Q;Chen X;Wu X;Liao R;Huang P;Tan Y;Wang L;Ren G;Huang J;Dong C

文献摘要

参考文献

被引文献

相似文献

曹等人。结果表明,UGT8通过激活硫脂-αVβ5轴而促进肺泡细胞癌的进展。ZA被认为是UGT8的直接抑制剂,可以抑制BLBC的进展,这表明抑制UGT8为治疗BLBC提供了一个有希望的机会。基底细胞样乳腺癌(BLBC)是一种临床预后较差的肿瘤,其治疗方案较少,治疗效果较差。在这里,我们报告尿二磷酸-半乳糖神经酰胺半乳糖基转移酶(UGT8)的高表达在BLBC中特异地发生,并预测乳腺癌患者的不良预后。Sox10在转录水平上上调UGT8的表达,触发硫脂生物合成途径;增加的硫脂激活整合素αVβ5介导的信号转导,促进白血病的进展。UGT8表达促进,而UGT8基因敲除抑制肿瘤的发生和转移。重要的是,我们确定唑来膦酸(ZA)是一种治疗骨质疏松症和骨转移的上市药物,是UGT8的直接抑制剂,UGT8可以阻断硫脂生物合成途径。值得注意的是,临床可获得的剂量的ZA对BLBC细胞的迁移、侵袭和肺转移具有明显的抑制作用。综上所述,我们的研究表明,UGT8是BLBC一个潜在的预后指标和可用药靶点,ZA对UGT8的药理抑制为治疗这种具有挑战性的疾病提供了一个有希望的机会。
Cao et al. show that UGT8 promotes BLBC progression through activating sulfatide–αVβ5 axis. ZA is identified as a direct inhibitor of UGT8 and suppresses BLBC progression, suggesting that inhibition of UGT8 offers a promising opportunity for treating BLBC. Basal-like breast cancer (BLBC) is associated with a poor clinical outcome as a result of the few treatment options and poor therapeutic response. Here, we report that elevated expression of urine diphosphate–galactose ceramide galactosyltransferase (UGT8) specifically occurs in BLBC and predicts poor prognosis in breast cancer patients. UGT8 expression is transcriptionally up-regulated by Sox10, triggering the sulfatide biosynthetic pathway; increased sulfatide activates integrin αVβ5-mediated signaling that contributes to BLBC progression. UGT8 expression promotes, whereas UGT8 knockdown suppresses tumorigenicity and metastasis. Importantly, we identify that zoledronic acid (ZA), a marketed drug for treating osteoporosis and bone metastasis, is a direct inhibitor of UGT8, which blocks the sulfatide biosynthetic pathway. Significantly, a clinically achievable dosage of ZA exhibits apparent inhibitory effect on migration, invasion, and lung metastasis of BLBC cells. Together, our study suggests that UGT8 is a potential prognostic indicator and druggable target of BLBC and that pharmacologic inhibition of UGT8 by ZA offers a promising opportunity for treating this challenging disease.
DOI: 10.1001/jama.2011.593
发表时间: 2011-05-11
期刊: JAMA
影响因子: --
作者:
Hatzis C;Pusztai L;Valero V;Booser DJ;Esserman L;Lluch A;Vidaurre T;Holmes F;Souchon E;Wang H;Martin M;Cotrina J;Gomez H;Hubbard R;Chacón JI;Ferrer-Lozano J;Dyer R;Buxton M;Gong Y;Wu Y;Ibrahim N;Andreopoulou E;Ueno NT;Hunt K;Yang W;Nazario A;DeMichele A;O'Shaughnessy J;Hortobagyi GN;Symmans WF
通讯作者: Symmans WF
DOI: 10.1158/1078-0432.ccr-09-0317
发表时间: 2009-07-15
影响因子: 11.5
作者:
Hoeflich, Klaus P.;O'Brien, Carol;Lackner, Mark R.
通讯作者: Lackner, Mark R.
DOI: 10.1073/pnas.93.23.13280
发表时间: 1996-11-12
影响因子: 11.1
作者:
Bosio, A;Binczek, E;Stoffel, W
通讯作者: Stoffel, W
DOI: 10.1016/s1470-2045(14)70302-x
发表时间: 2014-08-01
期刊: LANCET ONCOLOGY
影响因子: 51.1
作者:
Coleman, Robert;Cameron, David;Marshall, Helen
通讯作者: Marshall, Helen
DOI: 10.1006/geno.1996.0342
发表时间: 1996-07-01
期刊: GENOMICS
影响因子: 4.4
作者:
Bosio, A;Binczek, E;Stoffel, W
通讯作者: Stoffel, W